title: Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group.
abstract: The objective of this study was to determine the efficacy of gabapentin as adjunctive therapy in doses required to achieve the most effective seizure control. There were 2016 patients with partial seizures requiring adjunctive therapy who received gabapentin at doses up to 3600 mg/day in this open-label, multicenter, 16-week study. Of the 1055 patients evaluable for efficacy, 573 received gabapentin < or =1800 mg/day and 482 received > 1800 mg/day as the highest dose received. For the overall efficacy evaluable population, the percentage of patients achieving at least a 50% reduction in seizure frequency was 76.0%; 46.4% of the patients were seizure free. Patients whose highest gabapentin dose did not require > 1800 mg/day had, at baseline, fewer seizures and were receiving fewer concomitant antiepileptic drugs (AEDs) at baseline than those patients requiring > 1800 mg/day. This suggests that patients requiring higher doses of gabapentin were more refractory to drug treatment at the start of the study. Gabapentin was well tolerated at all doses in this study. The results of the study demonstrate that gabapentin is effective as adjunctive therapy in patients with partial seizures whose seizures are inadequately controlled by traditional AEDs.
authors.affiliation: Columbia University, The Neurological Institute, New York, NY, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Morrell
authors.forename: M J
authors.initials: MJ
authors.lastname: McLean
authors.forename: L J
authors.initials: LJ
authors.lastname: Willmore
authors.forename: M D
authors.initials: MD
authors.lastname: Privitera
authors.forename: R E
authors.initials: RE
authors.lastname: Faught
authors.forename: G L
authors.initials: GL
authors.lastname: Holmes
authors.forename: L
authors.initials: L
authors.lastname: Magnus
authors.forename: P
authors.initials: P
authors.lastname: Bernstein
authors.lastname: Rose-Legatt
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D000077206:Gabapentin; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin